Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-cash Items: 2014-2024

  • Zevra Therapeutics' Non-cash Items fell 78.36% to $2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 78.36%. This contributed to the annual value of $2.4 million for FY2024, which is 78.36% down from last year.
  • As of Q4 2024, Zevra Therapeutics' Non-cash Items stood at $2.4 million, which was down 78.36% from $11.1 million recorded in Q4 2023.
  • In the past 5 years, Zevra Therapeutics' Non-cash Items ranged from a high of $11.8 million in Q4 2022 and a low of $254,207 during Q4 2021.
  • Over the past 3 years, Zevra Therapeutics' median Non-cash Items value was $11.1 million (recorded in 2023), while the average stood at $8.4 million.
  • In the last 5 years, Zevra Therapeutics' Non-cash Items skyrocketed by 4,549.36% in 2022 and then slumped by 78.36% in 2024.
  • Zevra Therapeutics' Non-cash Items (Quarterly) stood at $543,021 in 2020, then crashed by 53.19% to $254,207 in 2021, then spiked by 4,549.36% to $11.8 million in 2022, then declined by 6.18% to $11.1 million in 2023, then crashed by 78.36% to $2.4 million in 2024.
  • Its last three reported values are $2.4 million in Q4 2024, $11.1 million for Q4 2023, and $11.8 million during Q4 2022.